301 related articles for article (PubMed ID: 18546622)
1. Role of p53 and Rb in ovarian cancer.
Corney DC; Flesken-Nikitin A; Choi J; Nikitin AY
Adv Exp Med Biol; 2008; 622():99-117. PubMed ID: 18546622
[TBL] [Abstract][Full Text] [Related]
2. [Advances in origin and pathogenesis of epithelial ovarian cancer].
Liu CR; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):569-72. PubMed ID: 22169654
[No Abstract] [Full Text] [Related]
3. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
4. The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S; Bates V; Lord R; Green JA
Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
6. [Incidence of proapoptotic proteins p53 and p21 in epithelial ovarian tumors].
Gajewska M; Wielgoś M; Panek G; Marczewska J
Ginekol Pol; 2014 Feb; 85(2):111-6. PubMed ID: 24745156
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
8. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer.
Ozalp SS; Yalcin OT; Basaran GN; Artan S; Kabukcuoglu S; Minsin TH
Eur J Gynaecol Oncol; 2000; 21(3):282-6. PubMed ID: 10949395
[TBL] [Abstract][Full Text] [Related]
10. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).
Aunoble B; Sanches R; Didier E; Bignon YJ
Int J Oncol; 2000 Mar; 16(3):567-76. PubMed ID: 10675491
[TBL] [Abstract][Full Text] [Related]
11. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
12. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.
Flesken-Nikitin A; Choi KC; Eng JP; Shmidt EN; Nikitin AY
Cancer Res; 2003 Jul; 63(13):3459-63. PubMed ID: 12839925
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to p53 and K-ras mutations.
Taylor RR; Linnoila RI; Gerardts J; Teneriello MG; Nash JD; Park RC; Birrer MJ
Gynecol Oncol; 1995 Sep; 58(3):307-11. PubMed ID: 7545631
[TBL] [Abstract][Full Text] [Related]
15. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.
Thames HD; Petersen C; Petersen S; Nieder C; Baumann M
Strahlenther Onkol; 2002 Aug; 178(8):411-21. PubMed ID: 12240546
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
18. Genetically-defined ovarian cancer mouse models.
Morin PJ; Weeraratna AT
J Pathol; 2016 Jan; 238(2):180-4. PubMed ID: 26496815
[TBL] [Abstract][Full Text] [Related]
19. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
20. The origin of stroma surrounding epithelial ovarian cancer cells.
Akahane T; Hirasawa A; Tsuda H; Kataoka F; Nishimura S; Tanaka H; Tominaga E; Nomura H; Chiyoda T; Iguchi Y; Yamagami W; Susumu N; Aoki D
Int J Gynecol Pathol; 2013 Jan; 32(1):26-30. PubMed ID: 23202778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
